This study is about testing a drug called isatuximab with new medicines for people who have a type of blood cancer called relapsed or refractory myeloma (RRMM). The study will last for about 28 months or until certain conditions occur, like if the disease gets worse or the participant wants to stop. The term relapsed means the cancer has returned, and refractory means the cancer did not respond to treatment.

People who want to join must be at least 18 years old and have had at least two other treatments before. Some tests, like blood or urine tests, will be needed to check if the disease is measurable. Candidates must also agree to use birth control. They should not have other serious health problems, certain infections, or have had recent cancer treatments.

• Participants will receive treatment until the disease progresses, death, or they choose to stop.
• The study involves several substudies, each with specific rules for joining.
• People with certain health issues or recent treatments may not be eligible to participate.